Partager Partager sur facebook Partager sur twitter Partager sur google+
-A +A

imprimer la page

Sources du dossier

Bonvalot S. : Sarcomes des tissus mous de l’adulte, Etat des lieux, Ed. Convergence, 2012.

 

The ESMO/European Sarcoma Networking Group : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Soft tissue sarcomas and visceral sarcomas. Ann Oncol 2012, 23 Suppl 7: vii92‑vii99

 

The ESMO/European Sarcoma Network Working Group : Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2014, 25, Suppl. 3: iii113–iii123.

 

The ESMO/European Sarcoma Network Working Group : GIST. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2014, 25, Suppl 3: iii102–iii112.

 

Charbotel B., Fervers B., Droz J-P. Occupational exposures in rare cancers: a critical review of the literature. Critical Reviews in Oncology/Hematology 2013 Dec 14.

 

Maki RG. Soft tissue sarcoma as a model disease to examine cancer immunotherapy.Curr Opin Oncol. 2001 Jul;13(4):270-4

 

Bonvalot S., Missenart G., Rosset P.,Terrier P.,Le Péchoux C., Le Cesne A. : EMC appareil locomoteur. Principes du traitement chirurgical des sarcomes des tissus mous du tronc et des membres de l’adulte, Vol. 8, octobre 2013.

 

Société nationale française de gastro-entérologie (SNCFG): Thésaurus national de chirurgie digestive : tumeurs stromales gastro-intestinales (GIST), juillet 2015.

 

Fondation ARC / Ray-Coquard I.: Les sarcomes des tissus mous et des viscères, comprendre pour agir, août 2015.

 

Site Internet d’information sur les sarcomes : www.infosarcomes.org

 

Bonvalot S, Raut CP, Pollock RE, Rutkowski P, Strauss DC, Hayes AJ, Van Coevorden F, Fiore M, Stoeckle E, Hohenberger P, Gronchi A Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG.

Ann Surg Oncol. 2012 Sep;19(9):2981-91.

 

Le Loarer F. et coll.: SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nature Genetics 47, 1200–1205,sept. 2015.

 

Tirode F. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 2014 Nov;4(11):1342-53.

 

Bailly RA, Bosselut R, Zucman J, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Molecular and Cellular Biology. 1994;14(5):3230-3241.

 

Van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879-86.

 

Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.Lancet. 2016 Feb 10. pii: S0140-6736(15)01283-0.

 

Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Lancet. 2013 Jan 26;381(9863):295-302.

 

La Rédaction
08/04/2016